Meeting
2014 Genitourinary Cancers Symposium
Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.
Authors
Rana R. McKay
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay , Gustavo Enrique Rodriguez , Xun Lin , Ronit Simantov , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 437)
DOI
10.1200/jco.2014.32.4_suppl.437
Abstract #
437
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.
First Author: Lana Hamieh
Poster
2015 Genitourinary Cancers Symposium
Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.
First Author: Rana R. McKay
Poster
2014 Genitourinary Cancers Symposium
Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.
First Author: Avishay Sella
Poster
2012 ASCO Annual Meeting
Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.
First Author: Giuseppe Procopio